We are committed to bring hope and relief to patients and their families by developing innovative groundbreaking drugs within Alzheimer’s disease, pain and other devastating disorders.
Our vision is to become a leading neuroscience research and development company providing substantial value to patients and society.
AlzeCure Pharma’s strategy is to develop a broad portfolio of symptomatic, disease-modifying and preventive drugs for Alzheimer’s, pain and other severe illnesses through work based on the following four guidelines:
- The right patient: Focusing on genetically, clinically and pathologically defined diseases to increase the ability of clinical effect
- The right mechanism: The treatment acts on genetically associated signaling pathways in Alzheimer’s disease and other indications.
- The right clinical testing: The clinical studies are based on validated biomarkers and preclinical methods with good translationto humans.
- The right treatment: Small-molecule drugs that penetrate the blood brain barrier (BBB) and which are designed for safe, efficacious long-term treatment.